Clidinium Uses, Dosage, Side Effects & Safety Guide
Authoritative Clinical Reference
Navigation
DRUG NAME: Clidinium
Therapeutic Class: Anticholinergic (Antimuscarinic)
Subclass: Antispasmodic
Speciality: Gastroenterology
Schedule (India): H
Route(s): Oral
Formulations Available in India:
| Formulation | Strengths | Availability Status |
| Clidinium bromide tablets (single entity) | — | NOT AVAILABLE in India |
| Clidinium + Chlordiazepoxide tablets (FDC) | 2.5 mg + 5 mg | Available |
Important Note: Clidinium is NOT available as a single-entity formulation in India. It is marketed ONLY as a fixed-dose combination (FDC) with chlordiazepoxide. All dosing information below refers to this FDC.
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Irritable Bowel Syndrome (IBS) with Anxiety Component
Using FDC: Clidinium 2.5 mg + Chlordiazepoxide 5 mg
| Parameter | Recommendation |
| Starting dose | 1 tablet (Clidinium 2.5 mg + Chlordiazepoxide 5 mg) orally twice daily before meals |
| Titration | May increase to three times daily based on tolerance and symptom response |
| Usual maintenance dose | 1 tablet orally 2–3 times daily, before meals and at bedtime |
| Maximum dose | 4 tablets/day (Clidinium 10 mg/day) |
Clinical Notes:
- Administer 30 minutes before meals for optimal antispasmodic effect
- Short-term use recommended (2–4 weeks); reassess if prolonged therapy needed
- Not suitable for constipation-predominant IBS (IBS-C)
- Benzodiazepine component may cause dependence with prolonged use
2. Functional GI Disorders with Psychosomatic Overlay
| Parameter | Recommendation |
| Starting dose | 1 tablet orally twice daily |
| Titration | Increase to 3 times daily if required |
| Usual maintenance dose | 1 tablet 2–3 times daily before meals |
| Maximum dose | 4 tablets/day |
Clinical Notes:
- Useful when anxiety or stress exacerbates GI symptoms
- Not first-line for organic GI pathology
- Consider non-pharmacological measures concurrently
Secondary Indications – Adults (Off-label)
| Indication | Dose | Duration | Notes |
| Peptic ulcer disease – adjunctive (OFF-LABEL) | 1 tablet 2–3 times daily before meals | Short-term (1–2 weeks) | Largely obsolete; PPIs and H. pylori eradication are first-line; historical use only |
| Functional dyspepsia with anxiety (OFF-LABEL) | 1 tablet 2–3 times daily | Short-term trial (2–4 weeks) | Specialist only; consider when psychogenic overlay suspected |
Evidence Basis: Historical Indian gastroenterology practice; limited controlled data
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not applicable — Clidinium-containing products are NOT approved for paediatric use in India.
Secondary Indications – Paediatrics (Off-label)
Not applicable.
Age Restriction:
- NOT recommended below 18 years of age
- High risk of anticholinergic toxicity in children
- Benzodiazepine component poses additional safety concerns in developing brain
- No established paediatric dosing data available
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| Mild impairment (eGFR 60–89) | No specific adjustment; use with caution |
| Moderate impairment (eGFR 30–59) | Use with caution; increased risk of anticholinergic and CNS effects |
| Severe impairment (eGFR <30) | Avoid; poor clearance may lead to drug accumulation |
| Dialysis | Avoid; no specific data available |
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
| Mild impairment | Use with caution; monitor for enhanced sedation (chlordiazepoxide component) |
| Moderate impairment | Avoid unless essential; significantly reduced benzodiazepine clearance |
| Severe impairment | Contraindicated — risk of hepatic encephalopathy from benzodiazepine component |
CONTRAINDICATIONS
- Known hypersensitivity to clidinium, chlordiazepoxide, or other benzodiazepines
- Angle-closure glaucoma (or predisposition)
- Prostatic hypertrophy with urinary retention
- Myasthenia gravis
- Paralytic ileus or GI obstruction
- Obstructive uropathy
- Severe hepatic impairment (due to chlordiazepoxide)
- Severe respiratory insufficiency
- Acute pulmonary insufficiency
- Sleep apnoea syndrome
CAUTIONS
- Elderly patients: High sensitivity to both anticholinergic and CNS-depressant effects
- Cardiovascular disease: Risk of tachycardia from anticholinergic action
- GERD: May worsen reflux by reducing lower oesophageal sphincter pressure
- Chronic constipation: May exacerbate symptoms
- History of substance abuse or dependence: Benzodiazepine component carries abuse potential
- Depression: May worsen depressive symptoms; monitor mental status
- Debilitated patients: Enhanced drug effects likely
- Prolonged use (>4 weeks): Risk of benzodiazepine dependence; plan for gradual tapering
PREGNANCY
| Aspect | Recommendation |
| Overall safety | Avoid — benzodiazepine component associated with potential fetal harm |
| Risk category | Not formally classified; benzodiazepines are generally Category D equivalent |
| First trimester | Contraindicated — risk of congenital malformations with benzodiazepines |
| Third trimester/peripartum | Risk of neonatal withdrawal syndrome, floppy infant syndrome |
| Preferred alternatives | Mebeverine; hyoscine butylbromide (short-term) |
| Monitoring | Fetal movements; neonatal observation if inadvertent exposure near delivery |
LACTATION
| Aspect | Recommendation |
| Compatibility | Not recommended |
| Reason | Chlordiazepoxide excreted in breast milk; may cause infant sedation |
| Clidinium in milk | Limited data; anticholinergic effects possible |
| Effect on lactation | May suppress milk production (anticholinergic effect) |
| Preferred alternatives | Mebeverine; hyoscine butylbromide (if short-term antispasmodic needed) |
| Infant monitoring | Sedation, poor feeding, lethargy, poor weight gain |
ELDERLY
| Aspect | Recommendation |
| Starting dose | 1 tablet once daily (lowest effective dose) |
| Titration | Very slow; increase only after 3–5 days if tolerated |
| Key risks | Confusion, delirium, hallucinations, falls, urinary retention, constipation, paradoxical agitation |
| Benzodiazepine concerns | Increased sensitivity; higher risk of falls and cognitive impairment |
| General guidance | Avoid if possible; prefer mebeverine or hyoscine butylbromide as alternatives |
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Management |
| CNS depressants (opioids, alcohol, other benzodiazepines, sedating antihistamines) | Additive CNS and respiratory depression | Avoid combination; if essential, use lowest doses with close monitoring |
| MAO inhibitors | Risk of enhanced CNS effects; potential hypertensive crisis | Avoid combination |
| Other anticholinergics (TCAs, antihistamines, antipsychotics) | Additive anticholinergic toxicity | Avoid combination; assess total anticholinergic burden |
| Ketoconazole, itraconazole, erythromycin (CYP3A4 inhibitors) | Increased chlordiazepoxide levels | Monitor for enhanced sedation; consider dose reduction |
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Management |
| Prokinetics (metoclopramide, domperidone) | Pharmacodynamic antagonism (opposing GI effects) | Avoid co-prescription for same indication |
| Warfarin | Possible altered INR (chlordiazepoxide interaction) | Monitor INR more frequently |
| Antacids | May reduce clidinium absorption | Separate administration by 1–2 hours |
| Rifampicin | May reduce chlordiazepoxide efficacy (CYP induction) | Monitor for reduced effect |
| Levodopa | Reduced levodopa efficacy (anticholinergic effect) | Avoid in Parkinson’s patients |
COMMON ADVERSE EFFECTS
- Dry mouth
- Constipation
- Blurred vision
- Drowsiness, sedation
- Urinary hesitancy
- Dizziness
- Headache
- Nausea
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Notes |
| Acute angle-closure glaucoma | Medical emergency; discontinue immediately; urgent ophthalmology referral |
| Severe urinary retention | May require catheterisation; discontinue drug |
| Toxic megacolon | Rare but serious; discontinue; surgical consultation |
| Confusion, delirium, hallucinations | More common in elderly; discontinue immediately |
| Paradoxical reactions (agitation, aggression) | Discontinue; more common in elderly and children |
| Benzodiazepine dependence | Risk with use >4 weeks; gradual taper required on discontinuation |
| Withdrawal syndrome | Seizures, rebound anxiety if abruptly stopped after prolonged use |
| Hepatic dysfunction | Rare; discontinue if jaundice or elevated LFTs occur |
MONITORING REQUIREMENTS
| Phase | Parameters |
| Baseline | Rule out glaucoma, prostatic hypertrophy, GI obstruction; assess mental status; LFTs if prolonged use planned |
| After initiation | Response assessment at 1–2 weeks; monitor bowel habits, CNS effects, urinary symptoms |
| Long-term (if used >4 weeks) | LFTs periodically; assess for dependence; plan tapering strategy; reassess continued need |
BRANDS AVAILABLE IN INDIA
| Brand Name | Manufacturer | Composition |
| Librax® | Abbott | Clidinium 2.5 mg + Chlordiazepoxide 5 mg |
| Spaslibrax® | Sun Pharma | Clidinium 2.5 mg + Chlordiazepoxide 5 mg |
| Normaxin® | Intas | Clidinium 2.5 mg + Chlordiazepoxide 5 mg |
| Clidium Plus® | Various | Clidinium 2.5 mg + Chlordiazepoxide 5 mg |
Note: All marketed products in India are FDCs. Single-entity clidinium is NOT available.
PRICE RANGE (INR)
| Formulation | Approximate Price |
| Clidinium + Chlordiazepoxide tablet (FDC) | ₹4–₹10 per tablet |
- NLEM Status: Not included in NLEM 2022
- NPPA Control: Not price-controlled
- Government supply: Available through Jan Aushadhi stores as generic equivalent
CLINICAL PEARLS
- FDC-only availability: Clidinium is not available as monotherapy in India; always prescribe as combination with chlordiazepoxide and counsel accordingly.
- Not for IBS-C: Anticholinergic component may worsen constipation; prefer mebeverine for constipation-predominant IBS.
- Short-term use only: Limit to 2–4 weeks due to benzodiazepine dependence risk; plan tapering strategy if longer use anticipated.
- Avoid in elderly: High anticholinergic burden plus benzodiazepine effects create significant risk of confusion, falls, and urinary retention; mebeverine is a safer alternative.
- Screen for glaucoma and BPH: Absolute contraindications; always assess before prescribing.
- IBS with anxiety: This FDC is specifically suited for IBS with significant anxiety component; if anxiety is absent, consider mebeverine or dicyclomine instead.
VERSION
RxIndia v1.0 — 03 Feb 2026
REFERENCES
- CDSCO Product Database
- Indian Pharmacopoeia / National Formulary of India
- API Textbook of Medicine
- AIIMS Drug Formulary
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
- Indian Gastroenterology Association practice patterns
- Tertiary hospital protocols (gastroenterology)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.